AOD-9604 vs LL-37
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of AOD-9604 and LL-37 (also searched as LL-37 vs AOD-9604) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
AOD-9604 centers on metabolic, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (AOD-9604: 4 studies, Human evidence; LL-37: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •AOD-9604 is strongest for metabolic; LL-37 for healing.
- •Evidence: AOD-9604 Human evidence (4 studies) vs LL-37 Human evidence (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
AOD-9604 vs LL-37: side-by-side
| Metric | AOD-9604 | LL-37 |
|---|---|---|
| Class | Weight Loss | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 4 | 5 |
| Research level | Well Studied | Well Studied |
| Strongest effect | Metabolic & appetite | Healing & recovery |
| Healing & recovery | 3.0 | 5.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 4.0▲ | 0.0 |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 4.0▲ |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | AOD-9604 | LL-37 |
|---|---|---|
| Mechanism | Modified hGH fragment (176–191) | — |
| Route | Subcutaneous injection (research use) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is AOD-9604?
A GH-fragment–derived peptide primarily discussed for fat loss and body-composition change, sometimes with cartilage and joint-repair context.
Full AOD-9604 profile, mechanism & studies →What is LL-37?
### LL-37 Summary LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory, and wound healing properties. Its diverse functions make it a subject of interest in various fields of biomedical research.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 5.0/5 effect signal |
| Metabolic | AOD-9604 | 4.0/5 effect signal |
| Inflammation | LL-37 | 4.0/5 effect signal |
| Skin | AOD-9604 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack AOD-9604 and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
AOD-9604 vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
AOD-9604 has 4 approved studies indexed (Human evidence), and LL-37 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is AOD-9604 or LL-37 better?
It depends on your goal. AOD-9604 is strongest for metabolic; LL-37 for healing. LL-37 has more indexed studies (5). See the goal-by-goal breakdown above.
Is AOD-9604 or LL-37 better for weight loss?
AOD-9604 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, AOD-9604 or LL-37?
AOD-9604 has 4 approved studies indexed (Human evidence); LL-37 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack AOD-9604 and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of AOD-9604 vs LL-37?
AOD-9604: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is AOD-9604 or LL-37 FDA-approved?
AOD-9604 is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than AOD-9604?
For healing, LL-37 has the edge; for metabolic, AOD-9604 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
AOD-9604 and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.